By a News Reporter-Staff News Editor at Biotech Week -- A new study on Stem Cell Research is now available. According to news originating from Moscow, Russia, by NewsRx correspondents, research stated, "Most tumors are heterogeneous and many cancers contain small population of highly tumorigenic and intrinsically drug resistant cancer stem cells (CSCs). Like normal stem cell, CSCs have the ability to self-renew and differentiate to other tumor cell types."
Our news journalists obtained a quote from the research from Lomonosov Moscow State University, "They are believed to be a source for drug resistance, tumor recurrence and metastasis. CSCs often overexpress drug efflux transporters, spend most of their time in non-dividing Go cell cycle state, and therefore, can escape the conventional chemotherapies. Thus, targeting CSCs is essential for developing novel therapies to prevent cancer relapse and emerging of drug resistance. Nanocarrier-based therapeutic agents (nanomedicines) have been used to achieve longer circulation times, better stability and bioavailability over current therapeutics. Recently, some groups have successfully applied nanomedicines to target CSCs to eliminate the tumor and prevent its recurrence. These approaches include 1) delivery of therapeutic agents (small molecules, siRNA, antibodies) that affect embryonic signaling pathways implicated in self-renewal and differentiation in CSCs, 2) inhibiting drug efflux transporters in an attempt to sensitize CSCs to therapy, 3) targeting metabolism in CSCs through nanoformulated chemicals and field-responsive magnetic nanoparticles and carbon nanotubes, and 4) disruption of multiple pathways in drug resistant cells using combination of chemotherapeutic drugs with amphiphilic Pluronic block copolymers. Despite clear progress of these studies the challenges of targeting CSCs by nanomedicines still exist and leave plenty of room for improvement and development."
According to the news editors, the research concluded: "This review summarizes biological processes that are related to CSCs, overviews the current state of anti-CSCs therapies, and discusses state-of-the-art nanomedicine approaches developed to kill CSCs."
For more information on this research see: Can nanomedicines kill cancer stem cells? Advanced Drug Delivery Reviews, 2013;65(13-14):1763-1783. Advanced Drug Delivery Reviews can be contacted at: Elsevier Science Bv, PO Box 211, 1000 Ae Amsterdam, Netherlands. (Elsevier - www.elsevier.com; Advanced Drug Delivery Reviews - www.elsevier.com/wps/product/cws_home/505508)
The news correspondents report that additional information may be obtained from Y. Zhao, Lomonosov Moscow State University, Fac Chem, Lab Chem Design Bionanomat, Moscow 119899, Russia. Additional authors for this research include D.Y. Alakhova and A.V. Kabanov (see also Stem Cell Research).
Keywords for this news article include: Drugs, Moscow, Russia, Cancer, Eurasia, Oncology, Chemotherapy, Stem Cell Research
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC